Neurology (85 companies · 63 conditions)

Conditions

Amyotrophic Lateral Sclerosis 16 Rare Multiple Sclerosis 15 Alzheimer's Disease 14 Parkinson's Disease 13 Major Depressive Disorder 12 Duchenne Muscular Dystrophy 9 Rare Epilepsy 8 Myasthenia Gravis 7 Rare Schizophrenia 7 Bipolar Disorder 6 Frontotemporal Dementia 5 Rare Generalized Anxiety Disorder 5 Huntington's Disease 5 Rare Friedreich's Ataxia 4 Rare Lewy Body Dementia 4 Multiple System Atrophy 4 Rare Myotonic Dystrophy 4 Rare Attention Deficit Hyperactivity Disorder 3 Autism Spectrum Disorder 3 Chronic Pain 3 Dravet Syndrome 3 Rare Migraine 3 Post-Traumatic Stress Disorder 3 Rett Syndrome 3 Rare Substance Use Disorder 3 Facioscapulohumeral Muscular Dystrophy 2 Rare Infantile Spasms 2 Rare Narcolepsy 2 Rare Progressive Supranuclear Palsy 2 Rare Spinal Cord Injury 2 Stiff Person Syndrome 2 Rare Tourette Syndrome 2 Acute Pain 1 Aneurysmal Subarachnoid Hemorrhage 1 Angelman Syndrome 1 Rare Anorexia Nervosa 1 Charcot-Marie-Tooth Disease Type 2S 1 Rare Chronic Inflammatory Demyelinating Polyneuropathy 1 Rare Chronic Low Back Pain 1 CLN2 Batten Disease 1 Rare Cocaine Use Disorder 1 Delayed Sleep Phase Disorder 1 Dementia-Related Psychosis 1 Essential Tremor 1 Fragile X Syndrome 1 Rare Giant Axonal Neuropathy 1 Rare GNE Myopathy 1 Rare Guillain-Barré Syndrome 1 Insomnia 1 Ischemic Stroke 1 Jet Lag Disorder 1 Lennox-Gastaut Syndrome 1 Rare Limb-Girdle Muscular Dystrophy 1 Rare Motion Sickness 1 Non-24-Hour Sleep-Wake Disorder 1 Non-Fluent Variant Primary Progressive Aphasia 1 Rare Primary Periodic Paralysis 1 Rare Smith-Magenis Syndrome 1 Rare Spinal Bulbar Muscular Atrophy 1 Rare Spinal Muscular Atrophy 1 Rare Spinocerebellar Ataxia 1 Rare Tuberous Sclerosis Complex 1 Rare X-Linked Adrenoleukodystrophy 1 Rare

Companies

Ticker	Company	Therapeutic areas	In Neurology	Lead stage	Mkt cap	Programs
AARD	Aardvark Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	$25.6M	3
ACIU	AC Immune	Neurology Rare	10	Phase 3	$222M	11
ABOS	Acumen Pharmaceuticals	Neurology	4	Phase 2	$16.2M	4
ACET	Adicet Bio	ImmunologyNeurology+2 Rare	1	Phase 1	$28.6M	8
ATHE	Alterity Therapeutics	Neurology Rare	2	Phase 2	$46.4M	2
ALT	Altimmune	GI/HepatologyMetabolic+1	1	Phase 3	$405M	3
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	$3.79B	5
ANNX	Annexon	HematologyNeurology+2 Rare	3	Phase 3	$796M	6
ARVN	Arvinas	NeurologyOncology Rare	3	Approved	$420M	10
ATAI	Atai Beckley	Neurology	5	Phase 2	$2.73B	5
AUTL	Autolus Therapeutics	HematologyImmunology+3 Rare	1	Approved	$341M	12
AXSM	Axsome Therapeutics	Neurology Rare	10	Approved	$6.96B	15
CABA	Cabaletta Bio	DermatologyImmunology+2 Rare	1	Phase 2	$280M	8
CAPR	Capricor Therapeutics	Infectious DiseaseNeurology Rare	1	NDA Submitted	$523M	2
RNAC	Cartesian Therapeutics	ImmunologyNeurology+1 Rare	1	Phase 3	$230M	4
CRVO	CervoMed	Neurology Rare	4	Phase 2	$21.5M	4
CING	Cingulate	Neurology	1	NDA Submitted	$61.9M	1
CLNN	Clene	Neurology Rare	3	NDA Submitted	$56.9M	5
CGTX	Cognition Therapeutics	Neurology	2	Phase 2	$65.3M	2
CMPS	COMPASS Pathways	Neurology	3	NDA Submitted	$1.22B	3
CTNM	Contineum Therapeutics	NeurologyRespiratory Rare	3	Phase 2	$374M	4
COYA	Coya Therapeutics	Neurology Rare	2	Phase 2	$70.1M	6
CYDY	CytoDyn	NeurologyOncology	1	Phase 2	$338M	3
DFTX	Definium Therapeutics	Neurology	4	Phase 3	$4.47B	4
DYN	Dyne Therapeutics	MetabolicNeurology Rare	7	NDA Submitted	$3.39B	10
ELDN	Eledon Pharmaceuticals	ImmunologyMetabolic+1 Rare	1	Phase 2	$212M	3
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+3 Rare	2	Approved	$1.63B	17
EVMN	Evommune	DermatologyImmunology+1	1	Phase 2	$241M	6
GANX	Gain Therapeutics	MetabolicNeurology Rare	4	Phase 1	$45.0M	5
GHRS	GH Research	NeurologyWomen's Health	3	Phase 2	$1.28B	4
GRCE	Grace Therapeutics	Neurology	1	NDA Submitted	$38.9M	1
HRMY	Harmony Biosciences	MetabolicNeurology Rare	12	Approved	$1.94B	17
HELP	Helus Pharma	Neurology	3	Phase 3	$655M	3
IMUX	Immunic	GI/HepatologyNeurology	2	Phase 3	$106M	4
IMVT	Immunovant	ImmunologyNeurology Rare	2	Phase 3	$6.31B	5
IXHL	Incannex Healthcare	NeurologyRespiratory	1	Phase 2	$28.1M	2
INSM	Insmed	CardiovascularImmunology+3 Rare	2	Approved	$25.1B	15
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	7	Approved	$6.55B	29
KZIA	Kazia Therapeutics	NeurologyOncology Rare	1	Phase 2	$82.0M	13
KROS	Keros Therapeutics	NeurologyOncology Rare	2	Phase 3	$184M	5
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	3	NDA Submitted	$302M	7
LRMR	Larimar Therapeutics	Neurology Rare	1	NDA Submitted	$248M	1
LBRX	LB Pharmaceuticals	Neurology	3	Phase 3	$1.36B	3
LXEO	Lexeo Therapeutics	CardiovascularNeurology Rare	9	Phase 2	$237M	12
LCTX	Lineage Cell Therapeutics	MetabolicNeurology+1 Rare	1	Phase 2	$258M	12
LGVN	Longeveron	CardiovascularMetabolic+1 Rare	1	Phase 2	$5.8M	4
MPLT	MapLight Therapeutics	Neurology	4	Phase 2	$385M	6
MGTX	MeiraGTx	ImmunologyMetabolic+2 Rare	2	Phase 3	$864M	16
MESO	Mesoblast	CardiovascularGI/Hepatology+2 Rare	2	Approved	$1.85B	5
NGEN	NervGen Pharma	Neurology	3	Phase 3	$143M	3
NGNE	Neurogene	Neurology Rare	1	Phase 3	$506M	1
NRSN	NeuroSense Therapeutics	Neurology Rare	3	Phase 2	$3.2M	3
NAMS	NewAmsterdam Pharma	CardiovascularMetabolic+1	1	NDA Submitted	$2.27B	6
NKTX	Nkarta	ImmunologyNeurology+1 Rare	1	Phase 1	$124M	8
NRXP	NRX Pharmaceuticals	Neurology Rare	6	Approved	$103M	7
NRIX	Nurix Therapeutics	ImmunologyNeurology+1	1	Phase 3	$1.67B	13
OCS	Oculis Holding	NeurologyOphthalmology Rare	1	Phase 3	$417M	5
OMER	Omeros	HematologyNeurology+2 Rare	2	Approved	$1.22B	6
OVID	Ovid Therapeutics	Neurology Rare	3	Phase 2	$557M	4
KTTA	Pasithea Therapeutics	NeurologyOncology Rare	2	Phase 1	$19.3M	4
PEPG	PepGen	Neurology Rare	1	Phase 2	$171M	1
DTIL	Precision Biosciences	Infectious DiseaseMetabolic+1 Rare	2	Phase 1	$296M	5
PCSA	Processa Pharmaceuticals	GI/HepatologyImmunology+2 Rare	1	Phase 2	$5.4M	7
PMN	ProMIS Neurosciences	Neurology Rare	6	Phase 1	$37.3M	6
PRQR	ProQR Therapeutics	MetabolicNeurology Rare	1	Phase 1	$191M	7
RAPP	Rapport Therapeutics	Neurology	6	Phase 3	$1.45B	10
RLMD	Relmada Therapeutics	MetabolicNeurology+1 Rare	2	Phase 2	$416M	4
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	7	Phase 3	$4.8M	10
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	10	Approved	$1.91B	11
SLDB	Solid Biosciences	CardiovascularNeurology Rare	2	Phase 3	$736M	6
STOK	Stoke Therapeutics	Neurology Rare	1	Phase 3	$1.74B	2
TSHA	Taysha Gene Therapies	Neurology Rare	3	Phase 3	$1.41B	4
TGTX	Tg Therapeutics	Neurology Rare	6	Approved	$9.16B	6
TLSA	Tiziana Life Sciences	ImmunologyNeurology Rare	4	Phase 2	$87.8M	5
RARE	Ultragenyx Pharmaceutical	CardiovascularMetabolic+1 Rare	1	Approved	$1.57B	10
QURE	uniQure	HematologyMetabolic+1 Rare	2	Approved	$1.52B	4
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	16	Approved	$231M	27
VKTX	Viking Therapeutics	MetabolicNeurology Rare	1	Phase 3	$3.42B	9
VOR	Vor Biopharma	ImmunologyNeurology Rare	1	Phase 3	$1.22B	2
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	8	Phase 1	$116M	9
WVE	Wave Life Sciences	MetabolicNeurology+1 Rare	2	Phase 2	$665M	5
XNCR	Xencor	ImmunologyNeurology+1 Rare	1	Approved	$2.68B	28
XENE	Xenon Pharmaceuticals	Neurology Rare	8	NDA Submitted	$3.79B	9
XERS	Xeris Biopharma	MetabolicNeurology Rare	1	Approved	$2.78B	4
ZBIO	Zenas BioPharma	DermatologyImmunology+2 Rare	3	NDA Submitted	$1.92B	11